IDEAYA Biosciences (IDYA)

IDEAYA Biosciences (IDYA) Income Statement


IDEAYA Biosciences Income Statement

Last quarter (Q2 2023), IDEAYA Biosciences's total revenue was $3.54M, a decrease of -39.43% from the same quarter last year. In Q2, IDEAYA Biosciences's net income was $-27.93M. See IDEAYA Biosciences’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 45.15M$ 50.93M$ 27.94M$ 19.54M$ 0.00$ 0.00
Cost of Revenue
Gross Profit
$ 15.45M$ 50.93M----
Operating Expense
$ 68.99M$ -113.43M$ 78.21M$ 54.88M$ 44.27M$ 36.42M
Operating Income
$ -84.77M$ -62.50M$ -50.27M$ -35.34M$ -44.27M$ -36.42M
Net Non Operating Interest Income Expense
$ 5.84M$ 3.85M$ 506.00K$ 849.00K$ 2.30M$ 2.07M
Other Income Expense
$ -4.78M---$ 8.00K$ 77.00K
Pretax Income
$ -74.15M$ -58.66M$ -49.76M$ -34.49M$ -41.98M$ -34.35M
Tax Provision
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -74.15M$ -58.66M$ -49.76M$ -34.49M$ -41.98M$ -34.35M
Basic EPS
$ -1.84$ -1.42$ -1.41$ -1.40$ -3.36$ -2.41
Diluted EPS
$ -1.48$ -1.42$ -1.41$ -1.40$ -3.36$ -2.41
Basic Average Shares
$ 186.37M$ 41.44M$ 35.25M$ 24.72M$ 12.50M$ 14.24M
Diluted Average Shares
$ 187.18M$ 41.44M$ 35.25M$ 24.72M$ 12.50M$ 14.24M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 68.99M$ -113.43M$ 78.21M$ 54.88M$ 44.27M$ 36.42M
Net Income From Continuing And Discontinued Operation
$ -74.15M$ -58.66M$ -49.76M$ -34.49M$ -41.98M$ -34.35M
Normalized Income
$ -20.45M-$ -49.76M$ -34.49M$ -41.98M$ -34.35M
Interest Expense
$ -79.99M$ -58.66M$ -50.27M$ -35.34M$ -44.27M$ -36.42M
$ -82.32M$ -57.25M$ -48.54M$ -33.96M$ -43.03M$ -35.53M
Currency in USD

IDEAYA Biosciences Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis